SCARB1 and cancer: According to previous reports (Shuo et al., 2013; David et al., 2015; Chang et al., 2017; Li et al., 2017), SR-BI is overexpressed in many types of cancer cells (breast, lymphoma, prostate, and ovarian), making its recognition a good platform for HDL-mediated targeted cancer drugs.